Page 3 - Randomised Evaluation News Today

Press release content from Business Wire. The AP news staff was not involved in its creation.

The Independent Data Monitoring Committee recommended that the EMPA-KIDNEY trial be stopped early, following a formal interim assessmentEMPA-KIDNE...

The FINANCIAL -- The RECOVERY trial has demonstrated that baricitinib reduces the risk of death when given to hospitalised patients with severe COVID-19. Baricitinib is an anti-inflammatory treatment normally used to treat rheumatoid arthritis. According to UKRI, the benefit was in addition to those of dexamethasone and tocilizumab, two other anti-inflammatory treatments that have previously beenThe FINANCIAL -- The RECOVERY trial has demonstrated that baricitinib reduces the risk of death when ...

Rheumatoid arthritis drug baricitinib can reduce risk of death from severe Covid by about a fifth

Corticosteroids have been advised as a drug to target the host immune response in patients affected with severe lung inflammation due to COVID-19.

Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement - read this article along with other careers information, tips and advice on BioSpace

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has extended the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.1 This ...

EMA's CHMP recommended the approval yesterdayApproval based on results from four phase III studies in over 5,500 patientsActemra/RoActemra has also been provisionally approved in Australia for the treatment

Investegate announcements from F. Hoffmann-La Roche Ltd, Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19

The CHMP recommends EU approval for Roche's (RHHBY) Actemra to treat patients with severe COVID-19.